Source: Novartis, Medicines for Malaria Venture (MMV) and EDCTP |

International research partnership and European & Developing Countries Clinical Trials Partnership (EDCTP) to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance

EDCTP ( grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV (, Novartis ( and other partners will provide an additional €22 million; The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica…